The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 19, 2020

Filed:

Mar. 12, 2019
Applicant:

Orsenix Holdings Bv, Wilmington, DE (US);

Inventors:

Krishna Vaddi, Kennett Square, PA (US);

Kumar Kurumaddali, New York, NY (US);

Assignee:

Orsenix Holdings BV, Wilmington, DE (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 33/36 (2006.01); A61K 31/285 (2006.01); A23C 1/06 (2006.01); A61K 9/19 (2006.01); A61K 9/48 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/20 (2006.01); A61K 47/26 (2006.01); A61K 47/02 (2006.01);
U.S. Cl.
CPC ...
A61K 9/19 (2013.01); A61K 9/48 (2013.01); A61K 9/4858 (2013.01); A61K 33/36 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/20 (2013.01); A61K 47/26 (2013.01);
Abstract

The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. Arsenic treatment has shown great promise in the treatment of several cancers but requires daily intravenous (IV) administration. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. As a result, the formulation facilitates a systemic bioavailability comparable to that of intravenous (IV) administration of arsenic trioxide currently practiced. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation.


Find Patent Forward Citations

Loading…